Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

The company’s most recent release (May 21, 2026) expands on the exclusive strategic marketing partnership with Mixed Martial Arts Group Limited (MMA.INC) that was first announced on May 12, 2026. The new details highlight the involvement of high‑profile MMA.INC strategic advisors — Conor McGregor, Donald Trump Jr., John Kavanagh, and board director Laura Sanko — and reinforces the revenue‑share structure: 50/50 in year one, shifting to 75/25 in Precision Peptide’s favor thereafter, with no upfront capital required. A companion industry‑commentary piece frames the partnership within a broader surge in peptide‑wellness investment, citing Eli Lilly’s Engage Biologics acquisition and Hims & Hers’ convertible note offering.

Earlier this month the company achieved a key product milestone: independent UHPLC‑DAD testing confirmed 95.5% purity of its lead needle‑free BPC‑157 transdermal patch and a quantified dose of 2.02 mg per patch. On May 7 an update indicated final testing is advancing toward commercial launch. The patch is being developed with the University of Alberta’s Drug Development and Innovation Centre (DDIC). Additionally, the company received C$1.3 million from warrant exercises (May 5) and has signed several marketing and PR service agreements (April‑May 2026). Regulatory tailwinds are present as the FDA has moved BPC‑157 toward Category 1 evaluation and the Pharmacy Compounding Advisory Committee will review it for the 503A Bulks List on July 23, 2026.

The May 21 news is Routine – Positive because it adds color to a partnership already disclosed on May 12, 2026. The core commercial terms (tiered revenue share, zero upfront investment) and the target audience (MMA.INC’s 5 million followers, 800+ gyms) were previously published. The naming of McGregor and Trump Jr. may amplify marketing buzz, but it does not alter the economic or operational substance of the deal. The patch purity result (May 19) is a tangible de‑risking event, yet that information arrived before the most recent release and had already moved the stock modestly (price rose from $0.42 to $0.44 on May 20). No new product, regulatory, or financing surprise appears in the latest news; it is an incremental positive news flow, consistent with the company’s narrative but not market‑moving on its own.

The Precision Peptide Company Inc. (CSE: BPC) develops and intends to commercialize peptide‑based wellness products. Its flagship project is a needle‑free, transdermal BPC‑157 patch — a wearable device designed to deliver the healing peptide without injections, reconstitution, or sterile handling. The patch has demonstrated 95.5% purity in independent lab testing (Miraxis Labs) and a measured dose of 2.02 mg per patch. The technology is supported by a research collaboration with the University of Alberta’s Drug Development and Innovation Centre (DDIC). A second product, the Immune Defense Patch (Thymosin Alpha‑1), is in the pipeline. The company also sells oral peptide formulations under the Amino Innovations brand, manufactured in a U.S.‑based, FDA‑compliant facility.